broad_id
string | depmap_id
string | ccle_name
string | screen_id
string | upper_limit
int64 | lower_limit
float64 | slope
float64 | r2
float64 | auc
float64 | ec50
float64 | ic50
float64 | name
string | moa
string | target
string | disease.area
string | indication
string | smiles
string | phase
string | passed_str_profiling
bool | row_name
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD-K33379087-001-07-5 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.129734 | 4.094844 | 0.678814 | 0.777706 | 0.838377 | 0.902177 | tivantinib | tyrosine kinase inhibitor | MET | null | null | O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23 | Phase 3 | true | ACH-000961 |
BRD-K33610132-001-02-9 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.179357 | 1.065411 | 0.63786 | 0.931219 | 7.396717 | null | rociletinib | EGFR inhibitor | EGFR | null | null | COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O | Phase 3 | true | ACH-000961 |
BRD-K35520305-001-16-9 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.973932 | -0.169532 | 0.008126 | 0.979615 | 211.3737 | null | dacarbazine | DNA alkylating agent | PGD, POLA2 | oncology, hematologic malignancy | melanoma, Hodgkin's lymphoma | CN(C)\N=N\c1[nH]cnc1C(N)=O, CN(C)\N=N\c1[nH]cnc1C(N)=O | Launched | true | ACH-000961 |
BRD-K36627727-001-05-4 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 1.011728 | -0.032568 | -0.020416 | 1 | 39,600,296.686042 | null | tamibarotene | retinoid receptor agonist | RARA, RARB | hematologic malignancy | acute promyelocytic leukemia (APL) | CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12 | Launched | true | ACH-000961 |
BRD-K36788280-001-01-2 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.800818 | -8.587589 | 0.177427 | 0.872372 | 0.306138 | null | ribociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1 | Launched | true | ACH-000961 |
BRD-K37379014-001-02-0 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.093178 | 2.741245 | 0.850268 | 0.746506 | 0.010354 | 0.011163 | filanesib | kinesin inhibitor, kinesin-like spindle protein inhibitor | KIF11 | null | null | CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F | Phase 3 | true | ACH-000961 |
BRD-K38332599-001-01-3 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.028811 | 1.007283 | 0.727112 | 0.735556 | 0.764276 | 0.810661 | uprosertib | AKT inhibitor | AKT1, AKT2, AKT3 | null | null | Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1 | Phase 2 | true | ACH-000961 |
BRD-K38527262-300-01-0 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.790294 | 0.082256 | -0.025302 | 0.90117 | 0.296549 | null | atiprimod | JAK inhibitor, STAT inhibitor | JAK2, STAT3 | null | null | CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1 | Phase 2 | true | ACH-000961 |
BRD-K38852836-001-02-1 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.271846 | 12.756832 | 0.843145 | 0.639278 | 0.020452 | 0.021749 | ganetespib | HSP inhibitor | HSP90AA1 | null | null | CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O | Phase 3 | true | ACH-000961 |
BRD-K39974922-001-04-3 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.957634 | -0.674494 | 0.019724 | 0.975591 | 0.173788 | null | lenvatinib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT4, KDR | oncology | thyroid cancer | COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O | Launched | true | ACH-000961 |
BRD-K41859756-001-06-8 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.338163 | 10.753156 | 0.756118 | 0.574409 | 0.004882 | 0.005422 | NVP-AUY922 | HSP inhibitor | HSP90AA1, HSP90AB1 | null | null | CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O | Phase 2 | true | ACH-000961 |
BRD-K42495768-001-01-7 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.686266 | 0.861229 | 0.152909 | 0.94218 | 2.209643 | null | tasisulam | apoptosis stimulant | null | null | null | Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1 | Phase 3 | true | ACH-000961 |
BRD-K42805893-001-04-9 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.806631 | 2.118343 | 0.127615 | 0.892954 | 0.025002 | null | osimertinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12 | Launched | true | ACH-000961 |
BRD-K42828737-001-03-3 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.837425 | 1.758378 | 0.168016 | 0.944954 | 0.150141 | null | sunitinib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET | oncology | gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET) | CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C | Launched | true | ACH-000961 |
BRD-K42898655-001-01-8 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.516172 | 0.516848 | 0.317395 | 0.640614 | 0.00026 | null | temsirolimus | mTOR inhibitor | MTOR | oncology | renal cell carcinoma (RCC) | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO | Launched | true | ACH-000961 |
BRD-K43389675-001-02-1 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.094066 | 7.278039 | 0.828601 | 0.731824 | 0.565413 | 0.581839 | daunorubicin | RNA synthesis inhibitor, topoisomerase inhibitor | TOP2A, TOP2B | hematologic malignancy | acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) | COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O | Launched | true | ACH-000961 |
BRD-K44227013-001-06-4 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 1.094164 | -0.089659 | -0.008515 | 1 | 0.031754 | null | ponatinib | Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1 | Launched | true | ACH-000961 |
BRD-K44408410-001-17-6 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.167582 | 3.58985 | 0.649583 | 0.910678 | 3.553544 | 3.981495 | 2-methoxyestradiol | hypoxia inducible factor inhibitor | COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB | null | null | COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O | Phase 2 | true | ACH-000961 |
BRD-K44827188-001-06-0 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.959706 | 1.348835 | -0.038613 | 0.971537 | 0.010373 | null | vismodegib | hedgehog pathway inhibitor, smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | Clc1cc(ccc1C(=O)Nc1ccc(Cl)c(c1)-c1ccccn1)S(C)(=O)=O | Launched | true | ACH-000961 |
BRD-K46386702-001-02-1 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.714967 | 0.134542 | 0.070973 | 0.82279 | 0.001712 | null | ARRY-334543 | EGFR inhibitor | ERBB2 | null | null | C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 | Phase 2 | true | ACH-000961 |
BRD-K49328571-001-15-0 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.408799 | 0.102443 | -0.100891 | 0.827635 | 535.91448 | null | dasatinib | Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor | ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1 | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1 | Launched | true | ACH-000961 |
BRD-K49350383-001-14-5 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 2.140914 | 0.989651 | 0.596401 | 1 | 1.780794 | null | thioguanine | purine antagonist | IMPDH1, IMPDH2 | hematologic malignancy | acute myeloid leukemia (AML) | Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1 | Launched | true | ACH-000961 |
BRD-K50010139-001-01-5 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.591842 | 0.592428 | -0.027742 | 0.764856 | 0.034044 | null | poziotinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C | Phase 2 | true | ACH-000961 |
BRD-K50168500-001-07-9 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.788035 | 1.201824 | 0.354349 | 0.865058 | 0.020502 | null | canertinib | EGFR inhibitor | AKT1, EGFR, ERBB2, ERBB4 | null | null | Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl | Phase 3 | true | ACH-000961 |
BRD-K51313569-001-07-8 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.85385 | -1.577127 | -0.116359 | 0.95197 | 0.014744 | null | palbociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O | Launched | true | ACH-000961 |
BRD-K51791723-003-01-7 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.099278 | 7.678624 | 0.722632 | 0.842246 | 1.827399 | 1.880845 | P276-00 | CDK inhibitor | CDK1, CDK4, CDK9 | null | null | CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000961 |
BRD-K51967704-001-03-6 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.233803 | 11.655081 | 0.78818 | 0.732596 | 0.338121 | 0.356909 | BIIB021 | HSP inhibitor | HSP90AA1 | null | null | COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C | Phase 2 | true | ACH-000961 |
BRD-K52313696-001-12-3 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.68464 | -0.195963 | -0.027324 | 0.917442 | 0.000275 | null | tacedinaline | HDAC inhibitor | HDAC1 | null | null | CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N | Phase 3 | true | ACH-000961 |
BRD-K53414658-001-08-2 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.789464 | 0.25857 | -0.056278 | 0.890301 | 0.054086 | null | tivozanib | VEGFR inhibitor | FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB | null | null | COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC | Phase 3 | true | ACH-000961 |
BRD-K53972329-001-07-0 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.992542 | -0.348438 | 0.000998 | 0.994388 | 3.646668 | null | ruxolitinib | JAK inhibitor | JAK1, JAK2, JAK3, TYK2 | hematologic malignancy, hematology | myelofibrosis, polycythemia vera | N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12 | Launched | true | ACH-000961 |
BRD-K54256913-001-08-7 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.109695 | 2.319515 | 0.75924 | 0.727562 | 0.513427 | 0.571278 | MK-1775 | WEE1 kinase inhibitor | WEE1 | null | null | CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1 | Phase 2 | true | ACH-000961 |
BRD-K54955827-001-02-2 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.930965 | -0.215993 | -0.002135 | 0.946156 | 43.478254 | null | niraparib | PARP inhibitor | PARP1 | oncology | primary peritoneal cancer (PPC) | NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1 | Launched | true | ACH-000961 |
BRD-K54997624-001-06-0 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.852986 | -1.007873 | -0.004001 | 0.947024 | 0.019589 | null | alpelisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | null | null | Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F | Phase 3 | true | ACH-000961 |
BRD-K55187425-236-05-2 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.206609 | 0.643823 | 0.696388 | 0.48951 | 0.016729 | 0.03829 | rigosertib | cell cycle inhibitor, PLK inhibitor | PLK1 | null | null | COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1 | Phase 3 | true | ACH-000961 |
BRD-K56343971-001-14-8 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.874123 | 0.379186 | 0.01495 | 0.924512 | 0.020316 | null | vemurafenib | RAF inhibitor | BRAF, RAF1 | oncology | melanoma | CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F | Launched | true | ACH-000961 |
BRD-K56981171-001-02-8 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.26936 | 0.815686 | 0.49498 | 0.865907 | 2.330954 | 6.018694 | brigatinib | ALK tyrosine kinase receptor inhibitor, EGFR inhibitor | ALK, EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1 | Launched | true | ACH-000961 |
BRD-K57080016-001-15-9 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.8964 | -1.023063 | -0.179432 | 0.964466 | 0.016491 | null | selumetinib | MEK inhibitor | MAP2K1 | null | null | Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO | Phase 3 | true | ACH-000961 |
BRD-K57169635-001-04-5 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.184018 | 0.875177 | 0.617149 | 0.79992 | 1.075928 | 1.817677 | dacomitinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1 | Phase 3 | true | ACH-000961 |
BRD-K58435339-001-03-0 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.326476 | 12.89217 | 0.823211 | 0.665044 | 0.080162 | 0.087018 | AT13387 | HSP antagonist | HSP90AA1 | null | null | CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O | Phase 2 | true | ACH-000961 |
BRD-K58529924-001-01-5 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.814498 | -3.178017 | 0.168538 | 0.88868 | 0.218687 | null | ONC201 | AKT inhibitor, MAP kinase inhibitor | TNFSF10 | null | null | Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O | Phase 2 | true | ACH-000961 |
BRD-K58550667-001-08-7 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.188837 | 1.998735 | 0.736479 | 0.663503 | 0.011154 | 0.014141 | FK-866 | niacinamide phosphoribosyltransferase inhibitor | NAMPT | null | null | O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1 | Phase 2 | true | ACH-000961 |
BRD-K59317601-001-05-5 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.319643 | 0.868347 | 0.729919 | 0.618526 | 0.042541 | 0.137652 | MLN0128 | mTOR inhibitor | MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12 | Phase 2 | true | ACH-000961 |
BRD-K59369769-001-22-9 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.953491 | 0.062114 | -0.001863 | 0.992929 | 96,128,699,415.53148 | null | tozasertib | Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor | AURKA, AURKB, AURKC, LCK | null | null | CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1 | Phase 2 | true | ACH-000961 |
BRD-K60866521-001-07-1 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 1.081562 | 0.746456 | 0.055034 | 1 | 0.019357 | null | idelalisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1 | Launched | true | ACH-000961 |
BRD-K60997853-001-02-3 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.060829 | 1.563959 | 0.639501 | 0.847969 | 2.200989 | 2.391323 | PHA-848125 | CDK inhibitor, growth factor receptor inhibitor | CDK2, CDK4, CDK7, NTRK1 | null | null | CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21 | Phase 2 | true | ACH-000961 |
BRD-K61192372-001-08-9 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.721255 | -4.296508 | 0.337708 | 0.750978 | 3.562647 | null | capecitabine | DNA synthesis inhibitor, thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O | Launched | true | ACH-000961 |
BRD-K62008436-001-23-9 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.135571 | 4.159601 | 0.80352 | 0.607166 | 0.007593 | 0.008193 | paclitaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1 | oncology | ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC) | CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 | Launched | true | ACH-000961 |
BRD-K62196610-001-01-6 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.991747 | -0.20612 | -0.026656 | 0.996522 | 0.014826 | null | AVN-944 | inosine monophosphate dehydrogenase inhibitor | IMPDH1, IMPDH2 | null | null | CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1 | Phase 2 | true | ACH-000961 |
BRD-K62200014-003-10-5 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.678453 | 0.01482 | -0.026841 | 0.832126 | 0.0002 | null | anagrelide | phosphodiesterase inhibitor | PDE3A | hematology, hematologic malignancy | thrombocythemia, myeloproliferative neoplasms | Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl | Launched | true | ACH-000961 |
BRD-K62391742-001-09-7 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.756957 | -0.07729 | -0.034591 | 0.900017 | 0.000718 | null | venetoclax | BCL inhibitor | BCL2 | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 | Launched | true | ACH-000961 |
BRD-K62627508-001-01-5 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 1.32451 | 0.451403 | 0.113391 | 1 | 0.221961 | null | idasanutlin | MDM inhibitor | MDM2, TP53 | null | null | COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O | Phase 3 | true | ACH-000961 |
BRD-K63712959-001-01-8 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 1.025378 | -0.127348 | -0.013266 | 1 | 0.07431 | null | temoporfin | radical formation stimulant | null | oncology | head and neck squamous cell carcinoma (HNSCC) | Oc1cccc(c1)-c1c2CCc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1[nH]2 | Launched | true | ACH-000961 |
BRD-K64052750-001-22-5 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.381243 | 0.35219 | 0.364569 | 0.650925 | 0.031696 | 1.877848 | gefitinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1 | Launched | true | ACH-000961 |
BRD-K64881305-001-03-7 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.140431 | 4.820387 | 0.642791 | 0.471117 | 0.025513 | 0.027319 | ispinesib | kinesin inhibitor | KIF11 | null | null | CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1 | Phase 2 | true | ACH-000961 |
BRD-K66175015-001-12-4 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.202647 | 0.299269 | 0.44573 | 0.712879 | 0.732229 | 4.157392 | afatinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | oncology | non-small cell lung cancer (NSCLC) | CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1 | Launched | true | ACH-000961 |
BRD-K67844266-003-01-9 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.199964 | 3.872569 | 0.649996 | 0.80746 | 0.967599 | 1.104021 | pevonedistat | nedd activating enzyme inhibitor | NAE1, UBA3 | null | null | NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12 | Phase 2 | true | ACH-000961 |
BRD-K69001009-001-02-8 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 62.181971 | 1.051381 | 0.259107 | 1 | 1,420.264075 | null | golvatinib | VEGFR inhibitor | KDR, MET | null | null | CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1 | Phase 2 | true | ACH-000961 |
BRD-K69694239-001-02-2 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.231926 | 2.679327 | 0.785322 | 0.738249 | 0.366193 | 0.462116 | bardoxolone-methyl | nuclear factor erythroid derived, like (NRF2) activator | PPARG, STAT3 | null | null | COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 | Phase 3 | true | ACH-000961 |
BRD-K69776681-001-03-8 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.117271 | 0.844632 | 0.185179 | 0.372834 | 0.009052 | 0.012422 | volasertib | PLK inhibitor | PLK1 | null | null | CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O | Phase 3 | true | ACH-000961 |
BRD-K70301465-001-05-9 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.693916 | 0.172255 | 0.00743 | 0.921952 | 54.66598 | null | ibrutinib | Bruton's tyrosine kinase (BTK) inhibitor | BLK, BMX, BTK | hematologic malignancy | chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM) | Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C | Launched | true | ACH-000961 |
BRD-K70401845-001-15-7 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.472263 | 2.238328 | 0.707177 | 0.818382 | 0.354532 | 1.290471 | erlotinib | EGFR inhibitor | EGFR, NR1I2 | oncology | non-small cell lung cancer (NSCLC), pancreatic cancer | COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC | Launched | true | ACH-000961 |
BRD-K73838513-003-05-5 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.962698 | -2.371912 | -0.009146 | 0.965883 | 4.652654 | null | cinacalcet | calcium channel activator | CASR | endocrinology, nephrology, oncology | hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia | C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12 | Launched | true | ACH-000961 |
BRD-K74514084-003-09-2 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.859769 | 0.129594 | -0.026677 | 0.920401 | 0.00893 | null | pazopanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3 | oncology | renal cell carcinoma (RCC), soft tissue sarcoma (STS) | CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1 | Launched | true | ACH-000961 |
BRD-K75009076-001-02-1 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | -1.34102 | 5.295427 | 0.569097 | 0.978086 | 10.952105 | 8.56232 | SCH-900776 | CHK inhibitor | CDK2, CHEK1 | null | null | Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1 | Phase 2 | true | ACH-000961 |
BRD-K76239644-001-02-6 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.490094 | 1.516161 | 0.428152 | 0.755911 | 0.096068 | 1.275993 | BMS-690514 | EGFR inhibitor, VEGFR inhibitor | EGFR, ERBB2, FLT3, KDR | null | null | COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1 | Phase 2 | true | ACH-000961 |
BRD-K76674262-001-03-3 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.15798 | 5.27431 | 0.753345 | 0.603143 | 0.103172 | 0.110874 | homoharringtonine | protein synthesis inhibitor | RPL3 | hematologic malignancy | chronic myeloid leukemia (CML) | COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC | Launched | true | ACH-000961 |
BRD-K76908866-001-07-6 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.661296 | -0.347352 | 0.09149 | 0.836078 | 0.062277 | null | CP-724714 | EGFR inhibitor, protein tyrosine kinase inhibitor | ERBB2 | null | null | COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1 | Phase 2 | true | ACH-000961 |
BRD-K78431006-001-15-1 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.739006 | -0.010063 | -0.056674 | 0.865848 | 20.488259 | null | crizotinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl | Launched | true | ACH-000961 |
BRD-K79254416-001-21-8 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.949358 | -2.481383 | -0.01248 | 0.97193 | 0.132276 | null | decitabine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML) | Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1 | Launched | true | ACH-000961 |
BRD-K81016934-001-02-0 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 1.061313 | 0.032383 | -0.006553 | 1 | 0.00029 | null | INC-280 | c-Met inhibitor | MET | null | null | CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1 | Phase 2 | true | ACH-000961 |
BRD-K81418486-001-44-2 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | -0.093053 | 0.413933 | 0.48567 | 0.74887 | 3.268586 | 2.164154 | vorinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9 | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1 | Launched | true | ACH-000961 |
BRD-K81473043-001-19-5 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.259053 | 6.083223 | 0.707314 | 0.880748 | 0.131072 | 0.147784 | tanespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 3 | true | ACH-000961 |
BRD-K82135108-001-04-3 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.916269 | -0.281697 | -0.035262 | 0.963146 | 0.007778 | null | elesclomol | oxidative stress inducer | HSPA1A | null | null | CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1 | Phase 3 | true | ACH-000961 |
BRD-K82746043-001-19-3 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.284111 | 2.250677 | 0.400602 | 0.847725 | 1.274594 | 1.851099 | navitoclax | BCL inhibitor | BCL2, BCL2L1, BCL2L2 | null | null | CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 | Phase 2 | true | ACH-000961 |
BRD-K82818427-001-04-8 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 1.153617 | -0.262244 | -0.017619 | 1 | 0.023642 | null | batimastat | matrix metalloprotease inhibitor | ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8 | null | null | CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO | Phase 3 | true | ACH-000961 |
BRD-K83029223-001-01-3 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.194209 | 4.934973 | 0.830192 | 0.631633 | 0.007396 | 0.008171 | litronesib | kinesin-like spindle protein inhibitor | KIF11 | null | null | CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 | Phase 2 | true | ACH-000961 |
BRD-K83988098-001-02-0 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.226987 | 5.828435 | 0.434929 | 0.817853 | 0.015851 | 0.017585 | alvespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 2 | true | ACH-000961 |
BRD-K85402309-043-01-9 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.607094 | 0.003211 | -0.000848 | 0.830656 | 1,446,332,979,986,582,800,000,000,000,000,000,000 | null | dovitinib | EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB | null | null | CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O | Phase 3 | true | ACH-000961 |
BRD-K85606544-001-09-1 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.640473 | 1.382983 | 0.234242 | 0.823224 | 0.084679 | null | neratinib | EGFR inhibitor | EGFR, ERBB2, KDR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 3 | true | ACH-000961 |
BRD-K86118762-001-01-8 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.903841 | -1.311473 | 0.129066 | 0.947811 | 0.118421 | null | linsitinib | IGF-1 inhibitor | IGF1R, INSR, INSRR | null | null | C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 | Phase 3 | true | ACH-000961 |
BRD-K86972824-001-01-4 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 1.499052 | 5.677738 | 0.51384 | 1 | 7.176313 | null | oltipraz | nuclear factor erythroid derived, like (NRF2) activator | ANG | null | null | Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1 | Phase 3 | true | ACH-000961 |
BRD-K87737963-001-06-0 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.864334 | -0.869924 | 0.125786 | 0.920128 | 0.190083 | null | cyt387 | null | JAK1, JAK2, JAK3 | null | null | O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1 | Phase 3 | true | ACH-000961 |
BRD-K87782578-001-01-4 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.408359 | 9.239559 | 0.3611 | 0.934413 | 3.410181 | 4.097616 | AVL-292 | Bruton's tyrosine kinase (BTK) inhibitor | BTK, YES1 | null | null | COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1 | Phase 2 | true | ACH-000961 |
BRD-K87909389-003-03-4 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.063428 | 4.994612 | 0.863059 | 0.810889 | 0.466128 | 0.478963 | alvocidib | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM | null | null | CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000961 |
BRD-K88510285-001-17-8 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.081211 | 1.210412 | 0.792026 | 0.520996 | 0.015881 | 0.018385 | bortezomib | NFkB pathway inhibitor, proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA | hematologic malignancy | multiple myeloma, mantle cell lymphoma (MCL) | CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O | Launched | true | ACH-000961 |
BRD-K89014967-001-04-3 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 1.708914 | 2.452913 | 0.713534 | 1 | 2.286824 | null | AS-703026 | MEK inhibitor | MAP2K1, MAP2K2 | null | null | OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F | Phase 2 | true | ACH-000961 |
BRD-K92441787-001-04-1 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.544595 | -1.898726 | 0.277186 | 0.969955 | 0.000961 | null | bexarotene | retinoid receptor agonist | RXRA, RXRB, RXRG | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C | Launched | true | ACH-000961 |
BRD-K92723993-001-17-4 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 3.549288 | 1.684084 | 0.109969 | 1 | 42.591719 | null | imatinib | Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET | hematologic malignancy, oncology | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST) | CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1 | Launched | true | ACH-000961 |
BRD-K95142244-001-01-5 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.793171 | -1.142654 | 0.015513 | 0.969717 | 0.002084 | null | talazoparib | PARP inhibitor | PARP2 | null | null | Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1 | Phase 3 | true | ACH-000961 |
BRD-K96123349-236-02-8 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 1.524367 | 0.607007 | 0.642272 | 1 | 0.083339 | null | brequinar | dihydroorotate dehydrogenase inhibitor | DHODH | null | null | Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F | Phase 2 | true | ACH-000961 |
BRD-K98572433-001-02-9 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.230322 | 0.393572 | 0.234257 | 0.734052 | 0.619748 | 2.974914 | AZD8931 | EGFR inhibitor | EGFR, ERBB2, ERBB3 | null | null | CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC | Phase 2 | true | ACH-000961 |
BRD-K99113996-001-02-0 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.50508 | 0.617266 | 0.525173 | 0.777406 | 0.134003 | null | AZD2014 | mTOR inhibitor | MTOR | null | null | CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C | Phase 2 | true | ACH-000961 |
BRD-M97302542-001-04-4 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.816202 | 0.480125 | 0.010673 | 0.910857 | 0.093216 | null | dichloroacetate | pyruvate dehydrogenase kinase inhibitor | PDK1 | null | null | [Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl | Phase 3 | true | ACH-000961 |
BRD-A25234499-001-19-1 | ACH-000962 | OC314_OVARY | MTS010 | 1 | 1.142714 | -3.963633 | 0.057507 | 1 | 0.005761 | null | aminoglutethimide | glucocorticoid receptor antagonist | CYP11A1, CYP19A1 | endocrinology, oncology | Cushing's syndrome, breast cancer | CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1 | Launched | true | ACH-000962 |
BRD-A70858459-001-01-7 | ACH-000962 | OC314_OVARY | MTS010 | 1 | 0.747716 | 0.452871 | 0.021637 | 0.857981 | 0.036303 | null | estramustine | DNA alkylating agent | ESR1, ESR2, MAP1A, MAP2 | oncology | prostate cancer | C[C@]12CCC3C(CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)C1CC[C@@H]2O | Launched | true | ACH-000962 |
BRD-A74914197-001-02-9 | ACH-000962 | OC314_OVARY | MTS010 | 1 | 0.16439 | 4.467762 | 0.967808 | 0.575136 | 0.004496 | 0.004915 | pralatrexate | dihydrofolate reductase inhibitor | DHFR, TYMS | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 | Launched | true | ACH-000962 |
BRD-K02113016-001-19-6 | ACH-000962 | OC314_OVARY | MTS010 | 1 | -0.122764 | 1.430488 | 0.77999 | 0.888324 | 4.663176 | 3.999643 | olaparib | PARP inhibitor | PARP1, PARP2 | oncology | ovarian cancer | Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1 | Launched | true | ACH-000962 |
BRD-K02130563-001-11-4 | ACH-000962 | OC314_OVARY | MTS010 | 1 | 0.195256 | 15.998327 | 0.646719 | 0.596574 | 0.077116 | 0.07954 | panobinostat | HDAC inhibitor | HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | multiple myeloma | Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1 | Launched | true | ACH-000962 |
BRD-K03390685-001-01-7 | ACH-000962 | OC314_OVARY | MTS010 | 1 | 0.610796 | 3.465266 | 0.585926 | 0.858513 | 0.293663 | null | cobimetinib | MEK inhibitor | null | oncology | melanoma | OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1 | Launched | true | ACH-000962 |
BRD-K03406345-001-21-1 | ACH-000962 | OC314_OVARY | MTS010 | 1 | 0.463193 | 2.581541 | 0.251785 | 0.936725 | 3.252522 | 8.935523 | azacitidine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL) | Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000962 |
Subsets and Splits
No saved queries yet
Save your SQL queries to embed, download, and access them later. Queries will appear here once saved.